This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Lilly's Returning Cash to Shareholders With Generous Dividend, Stock Buybacks

Stocks in this article: LLYSNY

NEW YORK ( TheStreet) -- Eli Lilly (LLY) could be a solid investment.

The drug maker boasts a generous dividend yield, a substantial share buyback program, a new cancer drug and several promising drugs in development.

>>Read More: Warren Buffett’s Top 10 Dividend Stocks

Lilly -- whose shares traded Thursday morning at $63.16, up 16 cents -- has a dividend yield of 3.2%, compared with 1.9% for the Standard & Poor's 500 Index. The stock, which trades at 17.6 times this year's estimated earnings, has risen 23.5% so far this year, compared with an 8.2% gain for the S&P 500.

The company is the middle of $5 billion share buyback program which it launched last year.

In April, Lilly received approval for its stomach cancer drug, Cyramza. According to Bloomberg, analysts say the drug could generate $1 billion in annual sales. That would help offset the loss in sales from osteoporosis drug Evista, which lost patent protection in March, and the probable loss in sales from Cymbalta, a depression treatment that has been Lilly's top-selling drug but that will lose market exclusivity after this year,

>>Read More: Teva Dividend Could Be Cut by Bank of Israel’s Rate Cut

Last week, Lilly reported positive results for its late-stage studies of its psoriasis treatment, ixekizumab. It plans to submit the drug for regulatory review during the first half of next year.

On the diabetes front, in June, Abasria, an insulin made by Lilly that is similar to Sanofi's (SNY) Lantus, was backed by the European Medicines Agency's Committee for Medicinal Products for Human Use, paving the way for the drug's acceptance in the European Union. Sanofi is suing Lilly to block an introduction of Abasria in the U.S.

>>Read More: It’s No Coincidence – Stocks and Car Sales Are Both Frothy

At the time of publication, the author held no positions in any of the stocks mentioned.

This article is commentary by an independent contributor, separate from TheStreet's regular news coverage.


TheStreet Ratings team rates LILLY (ELI) & CO as a Buy with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation:

"We rate LILLY (ELI) & CO (LLY) a BUY. This is driven by a few notable strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income."

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,717.08 +255.76 1.55%
S&P 500 1,952.40 +25.29 1.31%
NASDAQ 4,453.2670 +70.42 1.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs